Emerging immunotherapies for bladder cancer - PubMed (original) (raw)
Review
Emerging immunotherapies for bladder cancer
Joseph W Kim et al. Curr Opin Oncol. 2015 May.
Abstract
Purpose of review: Inhibition of immune escape mechanisms, such as the programed death-ligand 1 pathway, has demonstrated rapid, durable responses in multiple tumor types, including advanced urothelial carcinoma. This review discusses emerging immunotherapies for urothelial carcinoma in various stages of clinical development.
Recent findings: Urothelial carcinoma has a high mutational burden, which may increase the number of tumor antigens and potentially enhance the ability of the immune system to recognize tumor cells as foreign. However, urothelial carcinoma can evade the immune system by downregulating tumor-antigen presentation, upregulating various immune checkpoints, and inactivating cytotoxic T cells. Immunotherapies for urothelial carcinoma target each of these steps to restore immune-mediated cytotoxicity. Many of these agents are in clinical trials for urothelial carcinoma.
Summary: Immunotherapies are active in urothelial carcinoma, but only in a fraction of patients, implying the presence of persistent immune escape. Identifying the mechanisms of immune escape and developing rational combinatorial regimens may make the benefit of immunotherapy accessible to a broader population.
Conflict of interest statement
Conflicts of interest
There are no conflicts of interest.
Figures
FIGURE 1.
Urothelial carcinoma-specific antitumor T-cell immunity (modified from Chen and Mellman [22■]). 1. Released bladder tumor antigens. 2. Antigen processing and presentation. 3. Tumor antigen-specific T-cell priming, activation, and expansion. 4. Cytotoxic T-cell trafficking and infiltration to the tumor microenvironment. 5. T-cell recognition and immune-mediated tumor-cell killing.
Similar articles
- Emerging role of immunotherapy in urothelial carcinoma-Immunobiology/biomarkers.
Sweis RF, Galsky MD. Sweis RF, et al. Urol Oncol. 2016 Dec;34(12):556-565. doi: 10.1016/j.urolonc.2016.10.006. Epub 2016 Nov 9. Urol Oncol. 2016. PMID: 27836246 Free PMC article. Review. - Is there a role for maintenance therapy after platinum chemotherapy in bladder cancer in the era of immune therapy?
Rassy E, Assi T, Kattan J. Rassy E, et al. Future Oncol. 2019 Dec;15(34):3877-3879. doi: 10.2217/fon-2019-0542. Epub 2019 Nov 15. Future Oncol. 2019. PMID: 31729240 No abstract available. - Immunotherapy with Checkpoint Blockade in the Treatment of Urothelial Carcinoma.
Siefker-Radtke AO, Apolo AB, Bivalacqua TJ, Spiess PE, Black PC. Siefker-Radtke AO, et al. J Urol. 2018 May;199(5):1129-1142. doi: 10.1016/j.juro.2017.10.041. Epub 2017 Nov 4. J Urol. 2018. PMID: 29113841 Review. - Immunotherapy for genitourinary tumors.
Nakayama T, Kitano S. Nakayama T, et al. Int J Urol. 2019 Mar;26(3):326-333. doi: 10.1111/iju.13902. Epub 2019 Feb 1. Int J Urol. 2019. PMID: 30710374 Review. - Emerging role of immunotherapy in urothelial carcinoma-Advanced disease.
Zibelman M, Ramamurthy C, Plimack ER. Zibelman M, et al. Urol Oncol. 2016 Dec;34(12):538-547. doi: 10.1016/j.urolonc.2016.10.017. Urol Oncol. 2016. PMID: 27888981 Review.
Cited by
- Prognostic values of the immune microenvironment-related non-coding RNA IGF2BP2-AS1 in bladder cancer.
Ding K, Zheng Z, Han Y, Huang X. Ding K, et al. Cell Cycle. 2022 Dec;21(23):2533-2549. doi: 10.1080/15384101.2022.2103898. Epub 2022 Jul 27. Cell Cycle. 2022. PMID: 35894701 Free PMC article. - The feasibility of proteomics sequencing based immune-related prognostic signature for predicting clinical outcomes of bladder cancer patients.
Jiang L, Chen S, Pan Q, Zheng J, He J, Sun J, Han Y, Yang J, Zhang N, Fu G, Gao F. Jiang L, et al. BMC Cancer. 2022 Jun 20;22(1):676. doi: 10.1186/s12885-022-09783-y. BMC Cancer. 2022. PMID: 35725413 Free PMC article. - Comprehensive analysis of the PD-L1 and immune infiltrates of N6-methyladenosine related long non-coding RNAs in bladder cancer.
Xue MQ, Wang YL, Wang JC, Wang XD, Wang XJ, Zhang YQ. Xue MQ, et al. Sci Rep. 2022 Jun 16;12(1):10082. doi: 10.1038/s41598-022-14097-x. Sci Rep. 2022. PMID: 35710698 Free PMC article. - Clinical Outcomes of Mixed Response to Pembrolizumab in Advanced Urothelial Carcinoma After Platinum-based Chemotherapy.
Furubayashi N, Negishi T, Sakamoto N, Tamura S, Morokuma F, Song Y, Hori Y, Tomoda T, Seki N, Kuroiwa K, Nakamura M. Furubayashi N, et al. In Vivo. 2021 Sep-Oct;35(5):2869-2874. doi: 10.21873/invivo.12575. In Vivo. 2021. PMID: 34410980 Free PMC article. - Immune Profiling Reveals Molecular Classification and Characteristic in Urothelial Bladder Cancer.
Yang L, Li A, Liu F, Zhao Q, Ji S, Zhu W, Yu W, Zhang R, Liu Y, Li W, Zhang Y. Yang L, et al. Front Cell Dev Biol. 2021 Mar 11;9:596484. doi: 10.3389/fcell.2021.596484. eCollection 2021. Front Cell Dev Biol. 2021. PMID: 33777927 Free PMC article.
References
- Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011; 61:69–90. - PubMed
- Sylvester RJ, van der Meijden AP, Oosterlinck W, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 2006; 49:465–466. - PubMed
- Milowsky MI, Kim WY. The geriatrics and genetics behind bladder cancer. Am Soc Clin Oncol Educ Book 2014; e192–e195. - PubMed
- Raghavan D, Burgess E, Gaston KE, et al. Neoadjuvant and adjuvant chemotherapy approaches for invasive bladder cancer. Semin Oncol 2012; 39:588–597. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials